| 000 | 02959 a2200697 4500 | ||
|---|---|---|---|
| 005 | 20250514192325.0 | ||
| 264 | 0 | _c20050208 | |
| 008 | 200502s 0 0 eng d | ||
| 022 | _a1530-6860 | ||
| 024 | 7 |
_a10.1096/fj.03-1050fje _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKaneider, Nicole C | |
| 245 | 0 | 0 |
_aThe immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. _h[electronic resource] |
| 260 |
_bFASEB journal : official publication of the Federation of American Societies for Experimental Biology _cAug 2004 |
||
| 300 |
_a1309-11 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_a1-Methyl-3-isobutylxanthine _xpharmacology |
| 650 | 0 | 4 |
_aAmyloid beta-Peptides _xpharmacology |
| 650 | 0 | 4 |
_aAmyloid beta-Protein Precursor _xpharmacology |
| 650 | 0 | 4 |
_aAndrostadienes _xpharmacology |
| 650 | 0 | 4 |
_aBombesin _xpharmacology |
| 650 | 0 | 4 |
_aCalcitonin Gene-Related Peptide _xpharmacology |
| 650 | 0 | 4 |
_aCell Movement _xdrug effects |
| 650 | 0 | 4 |
_aChemotaxis, Leukocyte _xdrug effects |
| 650 | 0 | 4 |
_aCholera Toxin _xpharmacology |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aFingolimod Hydrochloride |
| 650 | 0 | 4 |
_aGene Expression Regulation _xdrug effects |
| 650 | 0 | 4 |
_aHeterotrimeric GTP-Binding Proteins _xphysiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xpharmacology |
| 650 | 0 | 4 |
_aIndoles _xpharmacology |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _xcytology |
| 650 | 0 | 4 |
_aMaleimides _xpharmacology |
| 650 | 0 | 4 |
_aN-Formylmethionine Leucyl-Phenylalanine _xpharmacology |
| 650 | 0 | 4 |
_aNeuropeptides _xpharmacology |
| 650 | 0 | 4 |
_aPertussis Toxin _xpharmacology |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aPhosphotransferases (Alcohol Group Acceptor) _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPropylene Glycols _xpharmacology |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aProtein Processing, Post-Translational _xdrug effects |
| 650 | 0 | 4 |
_aRNA, Messenger _xbiosynthesis |
| 650 | 0 | 4 |
_aReceptors, Lysosphingolipid _xagonists |
| 650 | 0 | 4 | _aSecretogranin II |
| 650 | 0 | 4 |
_aSphingosine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aStaurosporine _xpharmacology |
| 650 | 0 | 4 |
_aTyrphostins _xpharmacology |
| 650 | 0 | 4 |
_aVasoactive Intestinal Peptide _xpharmacology |
| 650 | 0 | 4 | _aWortmannin |
| 700 | 1 | _aLindner, Julia | |
| 700 | 1 | _aFeistritzer, Clemens | |
| 700 | 1 | _aSturn, Daniel H | |
| 700 | 1 | _aMosheimer, Birgit A | |
| 700 | 1 | _aDjanani, Angela M | |
| 700 | 1 | _aWiedermann, Christian J | |
| 773 | 0 |
_tFASEB journal : official publication of the Federation of American Societies for Experimental Biology _gvol. 18 _gno. 11 _gp. 1309-11 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1096/fj.03-1050fje _zAvailable from publisher's website |
| 999 |
_c14913784 _d14913784 |
||